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Morphological alterations in astrocytes are characteristic for post mortem brains of
patients affected by major depressive disorder (MDD). Recently, a significant reduction in
the coverage of blood vessels (BVs) by aquaporin-4 (AQP-4)-positive astrocyte endfeet
has been shown in the prefrontal cortex (PFC) of MDD patients, suggesting that either
alterations in the morphology of endfeet or in AQP-4 distribution might be responsible
for the disease phenotype or constitute a consequence of its progress. Antidepressant
drugs (ADs) regulate the expression of several proteins, including astrocyte-specific
ones. Thus, they may target AQP-4 to induce morphological changes in astrocytes
and restore their proper shape or relocate AQP-4 to endfeet. Using an animal model
of depression, rats selectively bred for high anxiety-like behavior (HAB), we confirmed
a reduced coverage of BVs in the adult PFC by AQP-4-immunoreactive (AQP-4-IR)
astrocyte processes with respect to non-selected Wistar rats (NAB), thereby validating it
for our study. A further evaluation of the morphology of astrocyte in brain slices (ex vivo)
and in vitro using an antibody against the astrocyte-specific cytoskeletal protein glial
fibrillary acidic protein (GFAP) revealed that HAB astrocytes extended less processes
than NAB cells. Furthermore, short-term drug treatment in vitro with the AD fluoxetine
(FLX) was sufficient to increase the plasticity of astrocyte processes, enhancing their
number in NAB-derived cells and recovering their basal number in HAB-derived cells.
This enhanced FLX-dependent plasticity occurred, however, only in the presence of
intact AQP-4, as demonstrated by the lack of effect after the downregulation of AQP-4
with RNAi in both NAB and HAB cells. Nonetheless, a similar short-term treatment did
neither modulate the coverage of BVs with AQP-4-positive astrocyte endfeet in NAB
nor in HAB rats, although dosage and time of treatment were sufficient to fully recover
GFAP expression in HAB brains. Thus, we suggest that longer treatment regimes may
be needed to properly restore the coverage of BVs or to relocate AQP-4 to astrocyte
endfeet. In conclusion, FLX requires AQP-4 to modulate the plasticity of astrocyte
processes and this effect might be essential to re-establish a functional glia-vasculature
interface necessary for a physiological communication between bloodstream and brain
parenchyma.
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INTRODUCTION
Morphometric examinations of prefrontal cortical (PFC) regions
in post mortem brains of patients with major depressive disorder
(MDD) revealed alterations in the density of astrocytes, in
addition to neurons (Rajkowska et al., 1999; Rajkowska and
Stockmeier, 2013). Moreover, studies in animal models of
stress-induced depressive-like behaviors showed an additional
astrocyte pathology, with morphological diﬀerences aﬀecting
speciﬁcally this cell type (Czeh et al., 2006). Astrocytes extend
processes that wrap around synapses and blood vessels (BVs),
thereby regulating the functionality of neuronal circuits and
of the blood-brain barrier (BBB; Koehler et al., 2009; Parpura
et al., 2012). Recently, a cerebrovascular pathology has been
demonstrated in older subjects suﬀering of MDD and patients
who suﬀered a primary cerebrovascular disease additionally
showed symptoms of mood disorders (Miguel-Hidalgo et al.,
2013), thus suggesting a strong causal link between a vascular
pathology and MDD. Indeed, a recent study revealed a reduced
coverage of BVs by astrocytic endfeet positive for aquaporin-
4 (AQP-4) in the PFC of post mortem brains from MDD
patients (Rajkowska et al., 2013). AQP-4 is a plasma membrane
water-transporting protein which is speciﬁcally localized to
the endfeet of astrocyte processes, thereby regulating several
functional properties of such processes. Its regulation of water
permeability is particularly important for the modulation of
astrocyte plasticity, especially for the extension and migration of
astrocyte processes during neuronal activity or activity around
BVs (Papadopoulos and Verkman, 2013) and to maintain the
integrity of the BBB (Zhou et al., 2008). Because of their
localization at the BBB, astrocytes may additionally regulate the
transport of therapeutic drugs in/out of the brain through their
polarized endfeet which interact with BVs (Pardridge, 1999) and
mutations in proteins located to the endfeet can predict a positive
or negative response to antidepressants (ADs; Uhr et al., 2008).
Interestingly, a recent study has shown how ablation of the mouse
gene coding for AQP-4 could disrupt responses to ﬂuoxetine
(FLX) in a chronic stress model of depressive-like behavior
(Kong et al., 2009). Furthermore, aqp-4 knockout mice present
cognitive deﬁcits similar to those implicated in mood disorders
(Skucas et al., 2011) and exhibit an exacerbated depressive-like
behavioral response after corticosterone treatment, accompanied
by impaired astrocytic functions (Kong et al., 2014).
An essential mean to understand the neurobiological
underpinnings of brain pathologies is the use of animal models
which reproduce the main features of human diseases and
several animal models exist, which have been validated to study
MDD. Among them, rats selectively bred for high anxiety-related
behavior (HAB) have shown to be an appropriate tool (with
face, construct and predictive validity) to study molecular risk
factors which may predispose to develop depressive-like behavior
(Wegener et al., 2012). Although they have been extensively
characterized at behavioral and pharmacological levels, it is still
unknown whether they show an astrocyte pathology such as
the one described in MDD patients. Therefore, the ﬁrst aim of
our study was to determine if HAB rats are a proper animal
model to analyze astrocyte alterations in MDD and the role
of AQP-4 in depressive-like behavior. Then, we followed the
hypothesis that AQP-4 might be either reduced or mislocalized
in a depressive-like pathology, thus being absent from endfeet
and unable to fulﬁll its functional role(s) around BVs. Moreover,
as ADs target astrocytes (Czeh and Di Benedetto, 2013) and this
targeting might be relevant to treat neuropsychiatric disorders
(Di Benedetto and Rupprecht, 2013), we examined whether FLX
may require AQP-4 to mediate its pharmacological modulatory
eﬀects on morphological changes in astrocytes.
MATERIALS AND METHODS
Drugs
Fluoxetine was purchased from Sigma (Taufkirchen, Germany)
and was dissolved in water for in vitro experiments. For ex vivo
experiments, FLX was dissolved in phosphate buﬀer saline (PBS,
saline).
Animals and Drug Treatment
Adult male rats (10–12 weeks old, 280–350 g) selectively bred for
HAB onWistar background and weight-matched non-selectively
bred Wistar rats (NAB) were used in this study. Breeding of HAB
andNAB animals occured at the animal facilities of the University
of Regensburg. Animals were housed under standard laboratory
conditions in groups of four [12 hours (hrs) light: dark cycle, 22–
24◦C, lights on at 06:00 am, food and water ad libitum]. For drug
treatment, FLX was dissolved on the day of the injections. Rats
received an i.p. injection of either 0 (saline) or 10 mg/kg FLX
twice a day for 2 days. On day 3, the animals were anesthetized
with CO2 and perfused transcardially with PBS, followed by 4%
paraformaldehyde (PFA, Sigma) in PBS. Brains were removed
and post-ﬁxed O/N at 4◦C, cryoprotected in 25% sucrose in PBS
and cut coronally at 40μmon a cryostat. Sections were preserved
in a solution with 25% ethylene glycol, 25% glycerol in PBS at
−20◦C until further processed for IF–IHC. Animal experiments
were approved by the government of the Oberpfalz, Germany,
and performed in accordance with the Guide for the Care and
Use of Laboratory Animals by the National Institutes of Health,
Bethesda, MD, USA.
Cell Culture
Primary astrocytes (NAB and HAB) were isolated from cerebral
cortices of postnatal day 1 (P1) rat brains. In brief, brains
were isolated and cortices were dissected, cut in small pieces
and digested with 0.25% trypsin containing 1 mM EDTA for
20 min (min) at 37◦C with gentle shaking. The remaining
tissue pieces were triturated with a ﬁre-polished Pasteur-pipette
to yield dissociated cells. Cells were centrifuged at 90 × g
for 5 min, resuspended in DMEM supplemented with 10%
FCS, 2 mM GlutaMAXI, penicillin (100 units/ml), streptomycin
(100 μg/ml) and 0.1 mM MEM Non Essential Amino Acids
(Invitrogen, Darmstadt, Germany) and seeded on poly-d-lysine-
coated 75 cm2 ﬂasks (Bressler et al., 1980; Allen et al., 2001).
When astrocyte cultures reached 80–90% conﬂuency, ﬂasks were
shaked to detach non-astrocytic cells, trypsinized with 0.25%
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trypsin containing 1mMEDTA and seeded on 24-well plates with
glass coverslips at a density of about 1 × 105 cells/well.
RNA Interference (RNAi), Cell
Transfection and Drug Treatment
Short interfering RNAs (siRNAs) complementary to the
rat mRNA sequence coding for AQP4 were synthesized
(Dharmacon Research, Lafayette, CO). Two diﬀerent siRNAs
(si2, 5′-CGGACUGAUGUUACUGGUUUU-3′ and si3, 5′-
UCAAUUAUACCGGAGCCAGUU-3′) were selected, which
were previously published to be eﬀective in primary rat astrocytes
(Nicchia et al., 2005), together with a scrambled siRNA (scr,
5′- CCUAAGGUUAAGUCGCCCUUU-3′), which was used
as negative control. All sequences were submitted to a BLAST
search to verify their speciﬁc targeting of Aqp-4 mRNA (si2
and si3) and the lack of targeting of any sequence for scrRNA.
Transfections were performed using LipofectamineTM 2000
(Invitrogen), following manufacturer’s instructions. In brief,
24 h before transfection, medium was changed to medium
without antibiotics. Afterwards, the appropriate amount of each
siRNA to reach a ﬁnal working concentration of 50 nM was
diluted in Opti-MEM I Reduced Serum Medium (Invitrogen),
incubated at RT and then mixed with Opti-MEM I containing
the appropriate amount of Lipofectamine. After a 20 min
incubation time, this mixture was distributed on cells. Cells
were then growing for three additional days, before changing the
medium to medium without FCS 24 h before drug treatment.
FLX was administrated at a ﬁnal concentration of 10 μM for
48 h. Afterwards, cells were washed with PBS, ﬁxed in PFA 4%
for 20 min at room temperature (RT) and then washed again
with PBS and maintained at 4◦C until further processed for
immunoﬂuorescent-immunocytochemistry (IF-ICC).
Immunofluorescent-
Immunohistochemistry and
Immunocytochemistry (IF-IHC and
IF-ICC)
For IF-IHC in rat brains: sections from the prefrontal
cortex (PFC) were selected and washed thoroughly, before
permeabilization and blocking for 2 h in 0.5% Triton-X
100 + 2% Normal Goat Serum (NGS, Vector Labs, Biozol,
Eching, Germany) in PBS. Afterwards, they were incubated with
rabbit anti-AQP4 (1:200, Abcam, Cambridge, UK) together with
mouse anti-collagen IV (1:500, Sigma) antibodies or with mouse
anti-GFAP antibody (1:400, Sigma) in 0.5% TX 100 + 2% NGS
in PBS O/N at 4◦C. Sections were then incubated with the
respective secondary antibodies, the biotinylated anti-rabbit IgG
antibody (1:300, Jackson ImmunoResearch, Hamburg, Germany)
with anti-mouse-Cy3 (1:250, Jackson ImmunoResearch) in 1%
NGS in PBS for 2 h at RT. Afterwards, sections were washed
and further incubated with avidin anti-biotin Alexa Fluor 488
(1:1000, Invitrogen) together with DAPI (1:1000, Sigma) in 1%
NGS in PBS for additional 2 h at RT. Finally, all sections were
then washed and mounted on slides for confocal analysis.
For IF- ICC on primary astrocytes: cells were permeabilized
and blocked in 0.2% Triton-X 100 + 2% NGS in PBS for
1 h at RT. Afterwards, they were incubated O/N at 4◦C with
rabbit anti-AQP4 antibody (1:400, Abcam) together with mouse
anti-GFAP + mouse anti-S100ß (1:400 and 1:1000, respectively,
Sigma) in 1% NGS in PBS. Cells were then washed and
incubated 1 h with biotinylated anti-rabbit IgG antibody (Jackson
Immunoresearch, 1:300) and anti-mouse-Cy3 (1:200) in 1%
NGS in PBS and afterwards 1 h with avidin anti-biotin Alexa
Fluor 488 (1:1000) and DAPI (1:1000) in 1% NGS in PBS.
After washing, coverslips were mounted on slides with anti-
fadingmountingmedium (Aquapolymount, Polysciences Europe
GmbH, Eppelheim, Germany) and analyzed with confocal
microscopy.
Confocal Microscopy
Confocal microscopy was performed with an Olympus confocal
microscope (inverted type IX81, Olympus Europe Holding
GmbH, Hamburg, Germany). For experiments in adult brains
(IF-IHC), mean values for coverage were obtained from an
average of 10 images (20 optical sections, 1 μm Z-step size)
from at least two slices per each brain. For IF-ICC, an average
of 10–25 ﬁelds from each treatment condition were acquired
(1μmZ-step size) for morphological examination. The FluoView
FV1000 program (Version 2.1c; Olympus FluoView Resource
Center) was used to convert the images from the proprietary ﬁle
format (.oib) into tagged image ﬁle format (.tiﬀ) ﬁles for further
analysis.
Coverage Analysis
One (.tiﬀ) ﬁle was generated for each image which contained
two color channels: a red for BVs labeled with collagen IV
and a green for endfeet immunoreactive (IR) for AQP-4. The
area of co-localized immunolabeling in the region of interest
(ROI) was measured using a Demo version of AutoQuantX3
Program. Afterwards, to calculate the coverage index (area of
co-localization/total area of vessels), the area occupied by the
colocalizing pixels was divided by the total area occupied by the
red pixels (representing the BVs labeled with collagen IV). This
ratio was deﬁned as the “Coverage.”
Analysis of Processes
For morphological analysis: in a ﬁrst experiment (Figure 2C),
astrocytes were stained with GFAP and S100β to label astrocyte
processes and the program NeuronJ, a plugin of ImageJ (http://
www.imagescience.org/meijering/software/neuronj/) was used to
count the number of processes per cell, after converting images
from the confocal microscope into 8-bit color pictures to be
compatible with the NeuronJ Program. In a second experiment,
AQP-4 staining was used to evaluatewhether observed changes in
morphology correlated with changes in AQP-4 cellular content.
For the analysis, we marked cell boundaries using the “lasso”
tool of Photoshop CS3 and then evaluated AQP-4 signal intensity
using the Histogramm function. Also for the RNAi experiment
we used IF-ICC to identify and choose for the analysis cells
which showed a reduction in AQP-4 signal, indicative of an
eﬃcient downregulation. Only those cells with reduced signal
were further examined for the number of astrocyte processes per
cell.
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Statistical Analysis
To choose the appropriate statistical test, a normality test was
performed for each sample distribution. Data are plotted as
means ± SEM and N refers to the number of independent
experiments. A one-way ANOVA was used, followed by
Tukey HSD post hoc or Dunnett’s post hoc tests for multiple
comparisons. For comparisons between two groups, the unpaired
Student’s t-test was used. Analyses were performed with Prism
GraphPad program (GraphPad Software, Inc., La Jolla, CA,USA).
RESULTS
HAB Rats are a Valid Animal Model to
Study Changes in Coverage of Blood
Vessels by the Endfeet Protein
Aquaporin-4
First, we evaluated whether the HAB rats as the animal model
used for this study, showed a reduced coverage of BVs by
AQP-4-IR endfeet in the PFC, as it was shown in human
post mortem brains of MDD patients (Rajkowska et al., 2013).
Using immunohistochemistry to label brain slices (ex vivo)
with collagen IV, a speciﬁc marker of BVs, together with a
speciﬁc antibody against AQP-4, which is localized to the endfeet
of astrocytes surrounding BVs (Papadopoulos and Verkman,
2013), we revealed that in the PFC of HAB rats the BVs
showed a 60% reduction in coverage by AQP-4-IR endfeet with
respect to NAB rats, similar to the ﬁnding in MDD patients
[Figure 1; NAB, 0.16 ± 0.04, N = 8; HAB, 0.06 ± 0.02,
N = 7; Student’s t-test, t(1,13) = 2.198, ∗p < 0.05]. Thus,
HAB rats were validated as appropriate animal model for our
study.
The Number of Astrocyte Processes is
Reduced in HAB with Respect to NAB
Astrocytes and Fluoxetine Treatment can
Rescue this Deficit
To investigate whether the observed lack of coverage was
dependent on a primary morphological change in astrocyte
processes, causing only secondarily a loss of AQP-4-IR endfeet,
or on a mislocalization of AQP-4 protein from still intact
processes, we ﬁrst compared ex vivo how GFAP, an astrocyte-
speciﬁc cytoskeletal marker, was expressed in HAB and NAB
brains. As previously shown (Rajkowska and Miguel-Hidalgo,
2007), we observed a dramatic reduction in the complexity
of astrocytic arborization (Figure 2A), thereby suggesting that
a main change in the morphology of astrocyte processes
may underlie the reduced coverage of BVs in HAB rats. We
therefore took advantage of our primary cell culture model
using cortical astrocytes derived from both NAB and HAB rats
to deeper examine the observed morphological diﬀerences. We
thereby showed in vitro that HAB-derived astrocytes developed
a reduced number of processes with respect to NAB-derived
cells [Figures 2B(1,3),C, NAB C, 9.59 ± 0.75 (22 cells), HAB
C, 3.75 ± 0.75 (20 cells), ANOVA, F(1,3) = 23.91, with Tukey’s
FIGURE 1 | The coverage of blood vessels (BVs) by aquaporin-4
(AQP-4)-immunoreactive astrocytic endfeet is reduced in the PFC of
HAB rats with respect to NAB rats. (A) Representative photomicrographs
show immunofluorescent stainings for AQP-4 (in green) and collagen IV (to
label BVs, in red) in NAB (left) and HAB (right) rats. (B) The scattered plot
shows a reduction of about 60% in the coverage of BVs by AQP-4-positive
endfeet in HAB rats in comparison with NAB rats [NAB (N = 8), HAB (N = 7);
t(1,13) = 2.198, ∗p < 0.05]. Scale bar = 10 μm.
post hoc test, ∗∗∗p< 0.001]. As far as AQP-4 modulates extension
of astrocyte processes (Saadoun et al., 2005) and a lack of AQP-
4 impairs the recovery from a depressive-like phenotype upon
FLX treatment in aqp-4 knockout mice (Kong et al., 2009),
we then examined whether the lack of astrocyte processes in
HAB cells might be linked to an AQP-4 deﬁciency which might
thereafter disrupt responses to FLX. A short-term (48 h) FLX
administration signiﬁcantly increased the number of processes
in NAB astrocytes, indicating such a morphological change as
a FLX target. More interestingly, however, we observed that
this short drug treatment was also suﬃcient to signiﬁcantly
enhance the number of astrocyte processes in HAB cells,
thereby restoring the basal total number of processes per cell
[Figures 2B(2,4),C, NAB + FLX, 13.57 ± 0.95 (21 cells),
HAB + FLX, 8.94 ± 0.88 (16 cells), ANOVA with Tukey’s
post hoc test, ∗∗p < 0.01, ∗∗∗p < 0.001]. Thus, suggesting
that AQP-4 may not be functionally deﬁcient in HAB cells
to mediate FLX eﬀect, but maybe only transcriptionally or
translationally repressed. To clarify this aspect, since we in fact
observed an apparent reduced AQP-4 expression in HAB brains
(Figure 1A), we used a more quantitative method to estimate
whether AQP-4 could be less expressed in HAB astrocytes with
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FIGURE 2 | Continued
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FIGURE 2 | Continued
Morphological differences in astrocytes are evident in HAB brains and
HAB cells with respect to NAB and FLX can modulate astrocyte
morphology in vitro. (A) Representative photomicrographs for GFAP (red) in
brain slices (ex vivo) show a strong atrophy of astrocytes in the PFC of HAB
rats. DAPI (in blue) labels nuclei of single cells to help identifying cells and BVs.
Scale bar = 30 μm. (B) Representative photomicrographs show NAB (1 and
2) and HAB-derived (3 and 4) astrocytes before and after a 48 h FLX
treatment. Cells were labelled with DAPI (blue) and the astrocyte markers
GFAP and S100ß (red) to examine morphological changes. (C) The graph
shows a reduction of about 60% in the number of astrocyte processes in HAB
astrocytes in comparison with NAB cells and the effect of FLX in increasing
the number of processes in both cell types [ANOVA, F(1,3) = 23.91,
∗∗p < 0.01, ∗∗∗p < 0.001]. (D) Representative photomicrographs of
immunofluorescent stainings show NAB (1 and 2) and HAB-derived (3 and 4)
astrocytes before and after a 48 h FLX treatment. Cells were labelled with
DAPI (blue) and AQP-4 (green) to measure changes in AQP-4 content per cell.
(E) The graph shows a reduction of about 23% in the amount of AQP-4 in
HAB astrocytes in comparison with NAB cells. FLX reversed AQP-4 amount
to basal levels in HAB cells and significantly enhanced AQP-4 expression in
NAB cells. ANOVA, F(1,3) = 6.61, ∗p < 0.05. Scale bar = 10 μm.
respect to NAB ones. Because commercially available antibodies
against AQP-4 are better working in immunochemistry than
for western blot, we performed an immunochemical staining to
compare AQP-4 expression between NAB and HAB astrocytes
and to evaluate how such expression was modulated upon drug
administration. We thereby showed that indeed the expression of
AQP-4 in HAB astrocytes was 23% less intense in average than
in NAB cells, although the diﬀerence did not reach statistical
signiﬁcance (Figure 2E). More importantly, however, AQP-4
expression was signiﬁcantly increased by FLX treatment in NAB
astrocytes [Figures 2D(1,2),E, NAB C, 47.65 ± 3.17 (14 cells),
NAB + FLX, 67.06 ± 7.29 (14 cells), ANOVA, F(1,3) = 6.61,
with Tukey’s post hoc test, ∗p < 0.05], paralleling the increased
amount of astrocyte processes (Figure 2C). In addition, AQP-
4 expression was normalized in HAB cells after FLX treatment
[Figures 2D(3,4),E, HAB C, 36.71± 3.17 (14 cells), HAB + FLX,
49.46 ± 4.71 (14 cells)], corresponding to the rescued eﬀect on
numbers of processes.
Downregulation of AQP-4 Induces a
Reduction in Number of Astrocyte
Processes in NAB Cells and Hampers
both the Effect of FLX in NAB Cells and
its Rescue Effect in HAB Cells
To then evaluate whether AQP-4 might be responsible for the
altered morphology observed in HAB cells and whether it is
required for the rescue eﬀect upon FLX treatment in these cells,
we used RNAi to downregulate AQP-4 in primary astrocyte
from both NAB and HAB rats. For these experiments we used
siRNA sequences which already showed their AQP-4 knockdown
eﬃcacy in rat astrocytes (Nicchia et al., 2005). We thereby
revealed that AQP-4 was indeed necessary for NAB astrocytes
to form their processes, since its knockdown caused a reduction
in the total number of processes per cell. Moreover, AQP-4
knockdown caused a loss of response to FLX treatment [Figure 3,
NAB C, 9.33 ± 0.62 (15 cells), NAB scr, 12.6 ± 0.71 (15 cells),
NAB si2, 4.13 ± 0.72 (15 cells), NAB si3, 4.00 ± 0.46 (15 cells),
NAB+ FLX, 21.86± 1.35 (14 cells), NAB scr+ FLX, 19.36± 0.94
(14 cells), NAB si2 + FLX, 4.38 ± 0.75 (13 cells), NAB si3 + FLX,
4.5 ± 0.43 (12 cells), ANOVA, F(1,7) = 81.21, with Tukey’s post
hoc test, ∗∗p < 0.01, ∗∗∗p < 0.001 with respect to NAB C and
### p < 0.001 with respect to NAB scr]. In this experiment we
could observe a higher number of astrocyte processes in response
to FLX treatment than those measured in the ﬁrst experiment
(Figure 2C). However, baseline number of processes per cell
were very consistent, thereby suggesting that drug eﬀects may
vary among experiments. Therefore, we focused our analysis on
relative changes after FLX treatment and did not make speciﬁc
claims about absolute numbers.
Furthermore, because we measured a reduced amount of
AQP-4 in HAB cells, which correlated to the lowered number of
processes (Figure 2E), we additionally performed a knockdown
experiment in HAB astrocytes to verify whether such variations
in AQP-4 content might aﬀect the functional role of AQP-4 in
HAB cells too. We conﬁrmed that a partially reduced amount of
AQP-4 could indeed be quantiﬁed in control HAB cells (HAB
C) with respect to NAB C cells (Supplementary Figure S1),
which might have caused the reduced amount of processes per
cell in HAB astrocytes. However, a dysfunctional AQP-4 in HAB
astrocytes could be ruled out because FLX was still able to restore
the basal number of processes in these cells, whereas the eﬀect
of FLX was blunted in AQP-4 knockdown HAB astrocytes in
which FLX could not reactivate AQP-4 expression (Figure 2E).
Thus, further supporting the essential role of AQP-4 to mediate
the growth of processes upon FLX administration [Figure 4,
HAB C, 2.20 ± 0.47 (15 cells), HAB scr, 2.67 ± 0.61 (15 cells),
HAB si2, 2.27 ± 0.36 (15 cells), HAB si3, 3.71 ± 0.64 (14
cells), HAB + FLX, 13.79 ± 0.86 (14 cells), HAB scr + FLX,
15.36 ± 0.95 (14 cells), HAB si2 + FLX, 3.80 ± 0.66 (10 cells),
HAB si3 + FLX, 2.87 ± 0.38 (15 cells), ANOVA, F(1,7) = 73.00,
with Tukey’s post hoc test, ∗∗∗p < 0.001 with respect to HAB C
and ###p < 0.001 with respect to HAB scr]. In this experiment
we found that the siRNA si3 showed lower eﬃciency than si2 in
downregulating AQP-4, as it was already evident in NAB cells
(Supplementary Figure S1A). This lower eﬃcacy of si3 gave
the impression of an apparent lack of eﬀect on AQP-4 in HAB
cells (Supplementary Figure S1B), because in these cells the
basal AQP-4 content was already quite low. However, we could
still observe its functional eﬃcacy to block the eﬀect of FLX on
astrocyte processes. This ﬁnding further supported that only in
case of a genetic blockade of the drug-dependent increase of
AQP-4 expression in HAB cells, which hinders the normalization
of its expression (Figure 2E), the eﬀect of FLX on the extension
of processes was inhibited.
Short Term FLX Treatment Modulates
GFAP Expression but it is not Sufficient
to Affect Coverage of BVs by Astrocytic
Endfeet Neither in NAB Nor in HAB Rats
To verify in vivo whether the short-term treatment with FLX
was suﬃcient to modulate the coverage of BVs by AQP-4-IR
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FIGURE 3 | Knockdown of AQP-4 in NAB astrocytes induces a lack of processes per cell. (A,B) Photomicrographs show representative immunofluorescent
stainings for GFAP/S100ß (to label astrocytes, in red) and AQP-4 (in green). (C) The graph shows that FLX can induce an increased amount of astrocyte processes
in NAB C (control) and NAB scr (transfected with a scrambled siRNA) astrocytes, but not in cells transfected with siRNAs against the mRNA coding for AQP-4 (si2
and si3; ANOVA with Tukey HSD post hoc test, ∗∗p < 0.01, ∗∗∗p < 0.001 with respect to NAB C and ### p < 0.001 with respect to NAB scr). Scale bar = 20 μm.
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FIGURE 4 | Knockdown of AQP-4 in HAB astrocytes. (A,B) Photomicrographs show representative immunofluorescent stainings for GFAP/S100ß (to label
astrocytes, in red) and AQP-4 (in green). (C) The graph shows that FLX could still induce an increased amount of astrocyte processes in HAB C (control) and HAB
scr astrocytes, thereby suggesting the presence of a still functional AQP-4 to mediate such an effect. However, cells transfected with si2 and si3 did not show the
rescue effect after FLX treatment, as they remained lower than NAB (ANOVA with Tukey HSD post hoc test, ∗∗∗p < 0.001 with respect to HAB C and ### p < 0.001
with respect to HAB scr). Scale bar = 20 μm.
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endfeet, we initially injected a small group of NAB and HAB
rats with FLX for 48 h. Using IF-IHC on brain slices from the
PFC we could show that indeed 48 h were suﬃcient to modulate
the cytoskeletal protein GFAP, with a consequent full recover
of its reduced expression in HAB brains [Figure 5A(3’,4’), yet
suggesting that a drug eﬀect indeed occurred after the short-term
treatment. However, we observed that FLX did not induce any
signiﬁcant change in the coverage of BVs by AQP4-IR endfeet in
neither group of rats, although in NAB rats we found a higher
degree of variability in response to FLX with respect to HAB rats
[Figures 5B(1–4),C; NAB, 0.294 ± 0.017, N = 4; NAB + FLX,
0.379 ± 0.08, N = 4; HAB, 0.012 ± 0.004, N = 3; HAB + FLX,
0.008 ± 0.001, N = 3; ANOVA, F(1,3) = 15.44, with Tukey’s post
hoc test, ∗p < 0.05].
DISCUSSION
Several reports in the last years have suggested AQP-4 as an
essential brain protein for a variety of astrocytic functions,
among which water balance and K+ buﬀering are the mostly
known (Papadopoulos and Verkman, 2013). In addition to
that, more recent studies have evidenced a role of AQP-4 as
mediator of AD eﬃcacy (Kong et al., 2009) and as a “protective”
factor against corticosterone-induced depressive-like phenotype
accompanied by an astrocytic pathology (Kong et al., 2014),
proposing AQP-4 as a novel putative molecule aﬀected in the
etiopathogenesis of MDD. In accordance with these studies, the
examination of post mortem brains of MDD patients revealed
a lack of coverage of BVs with AQP-4-IR endfeet of astrocytes,
further supporting a role for AQP-4 in MDD (Rajkowska et al.,
2013). Morphological changes in astrocytes strongly correlate
with their functionality and it has been already shown that a
reduction in the soma size of hippocampal astrocytes characterize
the hippocampus of tree shrews after long-term psychosocial
stress, which induces depressive-like behavior (Czeh et al., 2006).
However, to identify risk factors which might predispose an
individual to develop a depressive disorder, we would need
an animal model which displays a depressive-like phenotype
with a strong genetic component. We therefore decided to
examine the morphology of astrocyte in HAB rats (Neumann
et al., 2011; Wegener et al., 2012). Using IF-IHC we could
indeed show that HAB rats show a similar reduction in the
coverage of BVs by AQP-4-IR endfeet in the PFC as described
in the human study by Rajkowska et al. (2013). Our results
demonstrate the validity of this animal model to study the
importance of an astrocyte pathology for MDD, in addition
to the Wistar-Kyoto rat strain (Gosselin et al., 2009), thereby
oﬀering an alternative animal model to examine the role of
astrocytes in MDD with a particular focus on glia-vasculature
dysfunctions.
Furthermore, the lack of AQP-4 positive endfeet observed in
the PFC of post mortem brains from MDD patients prompted us
to hypothesize that either the endfeet of astrocytes were primarily
morphologically aﬀected, becoming only secondarily devoid of
AQP-4 expression, or AQP-4 was dyslocalized, although astrocyte
processes remained unaﬀected. Using a staining for GFAP both
FIGURE 5 | Short-term treatment of NAB and HAB rats with FLX can
reverse the reduced GFAP expression in HAB rats, but it is not
sufficient to neither modulate coverage of BVs by AQP-4-IR endfeet in
NAB brains nor rescue the lack of coverage in HAB brains.
(A) Representative photomicrographs show immunofluorescent stainings for
GFAP (in green) and DAPI (in blue) in NAB (1,1’) and HAB (3,3’) brains, where
it is evident the atrophy of astrocyte processes shown by the reduced GFAP
staining in HAB brains (3’). Such a reduced GFAP expression could be
rescued by the short-term treatment with FLX (HAB + FLX, 4,4’). Scale
bar = 20 μm. (B) Representative photomicrographs shows that FLX did not
change the coverage of BVs by AQP-4-positive endfeet neither in NAB (1,2)
nor in HAB (3,4) treated rats. (C) The scattered plot shows that FLX did not
change the coverage of BVs by AQP-4-positive endfeet neither in NAB (1,2)
nor in HAB (3,4) treated rats after the short-term drug treatment [NAB,
0.294 ± 0.017, N = 4; NAB + FLX, 0.379 ± 0.08, N = 4; HAB,
0.012 ± 0.004, N = 3; HAB + FLX, 0.008 ± 0.001, N = 3; ANOVA,
F(1,3) = 15.44, with Tukey’s post hoc test, ∗p < 0.05]. Scale bar = 5 μm.
in brain slices and in our cell culture model, we showed that in
fact HAB cells did not show the same morphological complexity
in slices ex vivo and did not possess the same amount of
processes in vitro as NAB cells did, thus suggesting that astrocytes
from this animal model were primarily morphologically aﬀected.
Astrocyte endfeet are essential to maintain the integrity of the
BBB (Zhou et al., 2008), but also to mediate the uptake of several
substances from the bloodstream. We might speculate that their
impairment may explain the slow onset of AD action, as far as
the recovery of a properly functional BBB is ﬁrst necessary before
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 February 2016 | Volume 10 | Article 8
Di Benedetto et al. Fluoxetine Requires Aquaporin-4 for Astrocyte Plasticity
ADs can be eﬃciently transported into the brain parenchyma.
Therefore, we examined how NAB and HAB astrocytes were
reacting to the AD FLX in terms of process extension. To our
surprise, however, FLX induced an increased number of astrocyte
processes in both cells, suggesting that a lack of AQP-4 on the
BVs might not be a primary cause of disease, but may only
aﬀect the response to drug treatments. To better understand this
aspect, we used RNAi to downregulate AQP-4 and examined
how its knockdown was aﬀecting the response to FLX. We
thereby showed that, although control HAB astrocytes were still
able to protrude an increased number of astrocyte processes in
response to drug administration, both NAB and HAB transfected
with siRNA targeting the mRNA coding for AQP-4 were not
only becoming unable to protrude new astrocyte processes in
response to FLX treatment, but they were also losing pre-existing
ones (in NAB cells). Thus, suggesting that AQP-4 might exert
multiple roles: on the one hand, it is necessary to somehow
maintain astrocyte processes in shape, maybe through actin-
(Nicchia et al., 2008) or GFAP-mediated mechanisms, as far as
both these proteins may be important regulators of structural
changes; on the other hand, AQP-4 is necessary to mediate AD
eﬃcacy. The latter is actually in line with reports showing that
the mouse knockout for aqp-4 cannot recover from the stress-
induced depressive-like behavior after FLX treatment (Kong
et al., 2009). Our results from the RNAi experiments actually
suggest that the observed lack of response to FLX in aqp-4
knockouts may depend on a reduced number of processes in
astrocytes due to AQP-4 deﬁciency, which consequently hinders
a FLX-induced process extension necessary to recover a proper
astrocytic functionality. Although interesting, our results can
only provide limited evidence for either temporary or persistent
FLX eﬀects on astrocyte processes after the short-term treatment
used here. To clarify this point, washout experiment in cell
culture would be needed and, if resulting eﬀects turned out to be
stable enough, then cell culture of astrocytes from adult animals
treated with FLX might be important to further conﬁrm these
in vitro ﬁndings.
Our ex vivo results after short term treatment of NAB and
HAB animals with FLX did not show the rescue of coverage of
BVs by AQP-4-IR astrocyte processes, probably due to a delay in
the uptake of FLX in vivo or to an insuﬃcient time to relocate
AQP-4 to the endfeet, which might require longer treatment
exposures or the supportive role of other cell types, such as
endothelial cells, necessary to induce the localization of AQP-
4 to endfeet (Camassa et al., 2015). In fact, endothelial cells
would be the ﬁrst cells exposed to FLX, strongly suggesting future
studies to analyze their response to FLX and ADs in more details,
speciﬁcally to dissect the potential contribution of endothelial
cells to the polarized distribution of AQP-4 in response to drug
administration. Indeed, such studies should help to understand
the molecular motors which regulate AQP-4 distribution and
function. A better understanding of the mechanism(s) which
drive AQP-4 in its appropriate localization may be of help to
identify novel target molecules which could fasten the restoration
of coverage of BVs by endfeet of astrocytes enriched in AQP-4 to
favor the recovery of a functional BBB and substance exchange
between bloodstream and brain parenchyma.
Another possibility to explain the lack of rescue eﬀect that
we observed in HAB rats treated with FLX might rely on a
diﬀerence in the type of processes that might form after drug
administration. We indeed observed that HAB cells treated with
FLX are enriched in processes which appeared to be shorter than
those induced in NAB cells, suggesting that longer treatment
times may be necessary to fully recover an amount of astrocyte
processes with proper functionality, i.e., long enough to reach
and completely surround again BVs with their AQP-4-IR endfeet.
A similar study has been recently published, which showed that
the AD naltrexone could reverse an astrocytic atrophy revealed in
macaques with behavioral disorders (Lee et al., 2015).
Although Nicchia et al. (2008) have shown that stellation of
astrocytes does not directly depend on the presence of AQP-4,
we noticed that AQP-4 knockdown resulted in a lack of stellate
morphology and FLX was no longer able to induce such a stellate
phenotype in AQP-4 knockdown astrocytes. We cannot rule out
that such a phenotype is due to a primary disrupted actin or GFAP
cytoskeleton in HAB astrocytes, since we observed that GFAP is
strongly impaired in HAB brains. More studies are needed to
identify the speciﬁc molecular mechanisms behind the lack of
stellate morphology in HAB cells.
CONCLUSION
Our results show that AQP-4 might be necessary in order to
maintain astrocyte processes, which are the functional unit of
astrocytes at the BBB and around synapses (Kimelberg, 2010).
Moreover, we could show that the lack of AQP-4 impairs
the eﬀect of FLX in restoring basal amounts of processes per
cell. We think that a better understanding of the mechanisms
which drive AQP-4 to the endfeet and around BVs might
help to develop pharmacological compounds which could
reverse disease phenotypes with an astrocytic pathology, such as
MDD.
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FIGURE S1 | The analysis of pixel intensity for AQP-4 staining in NAB (A)
and HAB (B) cells revealed that both si2 and si3 showed a high degree of
downregulation in both cell types, although with different efficiencies.
However, the reduced efficiency of si3 in HAB cells could also be explained
through a general reduced amount of AQP-4 signal in HAB C cells with respect to
the NAB C (NAB C, 49.01 signal intensity [in arbitrary unit] and HAB C, 36.48).
ANOVA with Dunnett’s post hoc test, ∗p < 0.05, ∗∗p < 0.01.
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